Raymond James Maintains Outperform on AbbVie, Raises Price Target to $189-Report Released on 4th February 2024
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Gary Nachman maintains an Outperform rating on AbbVie (NYSE:ABBV) and raises the price target from $181 to $189 as of 4th February 2024.
February 05, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James maintains an Outperform rating on AbbVie and raises the price target from $181 to $189.
The increase in the price target by Raymond James reflects a positive outlook on AbbVie's stock, suggesting potential upside. This is likely to be viewed favorably by investors, potentially leading to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100